Dergiler / European Journal of Breast Health / 2021 / Cilt: 17 - Sayı: 2

The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey

Sayfa
137–144
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This relationship can be confirmed further by large-scale studies with more cases

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: BRCA1/2 genes play a role in the etiopathogenesis of 10%–30% of triple-negative breast cancer (TNBC).
📊
Temel Bulgular & Veri:This study aims to investigate the BRCA1/2 genes and the demographic and clinicopathological features in patients with TNBC.
💡
Sonuç & Katkı:This relationship can be confirmed further by large-scale studies with more cases
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: BRCA1/2 genes play a role in the etiopathogenesis of 10%–30% of triple-negative breast cancer (TNBC). This study aims to investigate the BRCA1/2 genes and the demographic and clinicopathological features in patients with TNBC. The study also examined the impact of cancer history of TNBC individuals’ relatives on the risk of BRCA1/2 mutation carriership rate.Materials and Methods: The BRCA1/2 genes of 65 women diagnosed with TNBC between 2011 and 2017 were investigated using next-generation sequencing. We analyzed the correlations of patients’ demographic and clinicopathologic parameters and family history with BRCA1/2 mutation status. We used the χ2-test, t-test, Mann-Whitney U test, and logistic regression statistical methods.Results: The BRCA1/2 mutation carrier rate was 16.9%. Patients who had BRCA1/2 mutations were compared with those who did not in terms of demographic and clinicopathological parameters. In the BRCA1/2 mutation carrier group, the Ki-67 index and the number of relatives with cancer were higher than the BRCA1/2 non-carrier group. Logistic regression analysis revealed that when the number of relatives with breast or ovarian cancer was ≥2, the risk of carrying the BRCA1/2 mutation increased by 15-fold. Regardless of the type of cancer (including cancers in other organs besides breast or ovary), the risk of carrying the BRCA1/2 mutation increased 1.3 times with each increase in the number of relatives with cancer for the patient with TNBC.Conclusion: In cases with a diagnosis of TNBC, a significant relationship exists between the number of relatives with cancer in the family history and the risk of carrying mutations in the BRCA1/2 genes. This relationship can be confirmed further by large-scale studies with more cases

🔖

Bu Makaleye Atıf Yap

DUZKALE, N., KANDEMİR, O. (2022). The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey. European Journal of Breast Health, Cilt: 17 - Sayı: 2, 137–144. https://ajindex.com/articles/510725

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018
  2. (PMID: 30207593) [CrossRef] 2. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triplenegative breast cancer. Cancer Res 2013
  3. (PMID: 23536562) [CrossRef] 3. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016
  4. (PMID: 26341644) [CrossRef] 4. Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS One 2017
  5. e0172324. (PMID: 28235003) [CrossRef] 5. Lippi G, Mattiuzzi C, Montagnana M. BRCA population screening for predicting breast cancer: for or against? Ann Transl Med 2017
  6. (PMID: 28758101) [CrossRef] 6. Li YT, Ni D, Yang L, Zhao Q, Ou JH. The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China. Eur J Med Res 2014
  7. (PMID: 24961674) [CrossRef] 7. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol 2015
  8. (PMID: 25971625) [CrossRef] 8. Beck AC, Yuan H, Liao J, Imperiale P, Shipley K, Erdahl LM, et al. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria. Am J Surg 2020
  9. (PMID: 31255259) [CrossRef] 9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991
  10. (PMID: 1757079) [CrossRef] 10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015
  11. (PMID: 25741868) [CrossRef] 11. Diaz Casas S, Lancheros García E, Sanchéz Campo A, Sanchez Pedraza R, Roman Vasquez V, Mendoza SD, et al. Clinical behavior of triple negative breast cancer in a cohort of Latin American women. Cureus 2019
  12. e4963. (PMID: 31453035) [CrossRef] 12. Cinkaya A, Akin M, Sengul A. Evaluation of treatment outcomes of triple-negative breast cancer. J Cancer Res Ther 20